Treatment strategies for diabetic patients suffering from erectile dysfunction

Bibliography

• Penson DF, Latini DM, Lubeck DP, et al. Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database. Diabetes Care 2003;26:1093-9
   PubMed Web of Science ®Google Scholar
• Khatib FA, Jarrah NS, Shegem NS, et al. Sexual dysfunction among Jordanian men with diabetes. Saudi Med J 2006;27:351-6
   PubMed Web of Science ®Google Scholar
• Sasaki H, Yamasaki H, Ogawa K, et al. Prevalence and risk factors for erectile dysfunction in Japanese diabetics. Diabetes Res Clin Pract 2005;70:81-9
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE. Ten-year incidence of self-reported erectile dysfunction in people with long-term type 1 diabetes. J Diabetes Complications 2005;19:35-41
   PubMedGoogle Scholar
• Chu NV, Edelman SV. Erectile dysfunction and diabetes. Curr Diab Rep 2002;2:60-6
   PubMedGoogle Scholar
• Moore CR, Wang R. Pathophysiology and treatment of diabetic erectile dysfunction. Asian J Androl 2006;8:675-84
   PubMed Web of Science ®Google Scholar
• Podlasek CA, Zelner DJ, Bervig TR, et al. Characterization and localization of nitric oxide synthase isoforms in the BB/WOR diabetic rat. J Urol 2001;166:746-55
   PubMed Web of Science ®Google Scholar
• Hecht MJ, Neundorfer B, Kiesewetter F, et al. Neuropathy is a major contributing factor to diabetic erectile dysfunction. Neurol Res 2001;23:651-4
   PubMed Web of Science ®Google Scholar
• Chen Y, Yang R, Yao L, et al. Differential expression of neurotrophins in penises of streptozotocin-induced diabetic rats. J Androl 2007;28:306-12
   PubMedGoogle Scholar
• Bennett NE, Kim JH, Wolfe DP, et al. Improvement in erectile dysfunction after neurotrophic factor gene therapy in diabetic rats. J Urol 2005;173:1820-4
   PubMed Web of Science ®Google Scholar
• Angulo J, Cuevas P, Gabancho S, et al. Enhancement of both EDHF and NO/cGMP pathways is necessary to reverse erectile dysfunction in diabetic rats. J Sex Med 2005;2:341-6
   PubMedGoogle Scholar
• Shirai M, Yamanaka M, Shiina H, et al. Vascular endothelial growth factor restores erectile function through modulation of the insulin-like growth factor system and sex hormone receptors in diabetic rat. Biochem Biophys Res Commun 2006;341:755-62
   PubMed Web of Science ®Google Scholar
• Park CS, Ryu SD, Hwang SY. Elevation of intracavernous pressure and NO-cGMP activity by a new herbal formula in penile tissues of aged and diabetic rats. J Ethnopharmacol 2004;94:85-92
   PubMedGoogle Scholar
• Bivalacqua TJ, Usta MF, Champion HC, et al. Gene transfer of endothelial nitric oxide synthase partially restores nitric oxide synthesis and erectile function in streptozotocin diabetic rats. J Urol 2003;169:1911-7
   PubMed Web of Science ®Google Scholar
• Escrig A, Marin R, Abreu P, et al. Changes in mating behavior, erectile function, and nitric oxide levels in penile corpora cavernosa in streptozotocin-diabetic rats. Biol Reprod 2002;66:185-9
   PubMed Web of Science ®Google Scholar
• Yildirim S, Ayan S, Sarioglu Y, et al. The effects of long-term oral administration of L-arginine on the erectile response of rabbits with alloxan-induced diabetes. BJU Int 1999;83:679-85
   PubMedGoogle Scholar
• Ari G, Vardi Y, Finberg JP. Nitric oxide and penile erection in streptozotocin-diabetic rats. Clin Sci 1999;96:365-71
   Google Scholar
• Simopoulos DN, Gibbons SJ, Malysz J, et al. Corporeal structural and vascular micro architecture with X-ray micro computerized tomography in normal and diabetic rabbits: histopathological correlation. J Urol 2001;165:1776-82
   PubMed Web of Science ®Google Scholar
• Lu YL, Shen ZJ, Wang H, et al. Ultrastructural changes of penile tunica albuginea in diabetic rats. Asian J Androl 2004;6:365-8
   PubMedGoogle Scholar
• Angulo J, Cuevas P, Fernandez A, et al. Enhanced thromboxane receptor-mediated responses and impaired endothelium-dependent relaxation in human corpus cavernosum from diabetic impotent men: role of protein kinase C activity. J Pharmacol Exp Ther 2006;319:783-9
   PubMedGoogle Scholar
• Chen Y, Li SX, Yao LS, et al. Valsartan treatment reverses erectile dysfunction in diabetic rats. Int J Impot Res 2007;19:366-70
   PubMedGoogle Scholar
• Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003;6:1-7
   PubMedGoogle Scholar
• Alexopoulou O, Jamart J, Maiter D, et al. Erectile dysfunction and lower androgenicity in type 1 diabetic patients. Diabetes Metab 2001;27:329-36
   PubMed Web of Science ®Google Scholar
• Bivalacqua TJ, Usta MF, Kendirci M, et al. Superoxide anion production in the rat penis impairs erectile function in diabetes: influence of in vivo extracellular superoxide dismutase gene therapy. J Sex Med 2005;2:187-97; discussion 197-8
   PubMed Web of Science ®Google Scholar
• Ryu JK, Lee T, Kim DJ, et al. Free radical-scavenging activity of Korean red ginseng for erectile dysfunction in non-insulin-dependent diabetes mellitus rats. Urology 2005;65:611-5
   PubMed Web of Science ®Google Scholar
• De Young L, Yu D, Bateman RM, et al. Oxidative stress and antioxidant therapy: their impact in diabetes-associated erectile dysfunction. J Androl 2004;25:830-6
   PubMedGoogle Scholar
• Usta MF, Kendirci M, Gur S, et al. The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin-induced diabetic rats: preventive versus curative treatment. J Sex Med 2006;3:242-50; discussion 250-2
   PubMed Web of Science ®Google Scholar
• Usta MF, Bivalacqua TJ, Yang DY, et al. The protective effect of aminoguanidine on erectile function in streptozotocin diabetic rats. J Urol 2003;170:1437-42
   PubMedGoogle Scholar
• Cartledge JJ, Eardley I, Morrison JF. Advanced glycation end-products are responsible for the impairment of corpus cavernosal smooth muscle relaxation seen in diabetes. BJU Int 2001;87:402-7
   PubMed Web of Science ®Google Scholar
• Seftel AD, Vaziri ND, Ni Z, et al. Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS. Urology 1997;50:1016-26
   PubMed Web of Science ®Google Scholar
• Vignozzi L, Morelli A, Filippi S, et al. Testosterone regulates RhoA/Rho-kinase signaling in two distinct animal models of chemical diabetes. J Sex Med 2007;4:620-30; discussion 631-2
   PubMed Web of Science ®Google Scholar
• Bivalacqua TJ, Champion HC, Usta MF, et al. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci USA 2004;101:9121-6
   PubMed Web of Science ®Google Scholar
• Hipp JD, Davies KP, Tar M, et al. Using gene chips to identify organ-specific, smooth muscle responses to experimental diabetes: potential applications to urological diseases. BJU Int 2007;99:418-30
   PubMedGoogle Scholar
• Davies KP, Zhao W, Tar M, et al. Diabetes-induced changes in the alternative splicing of the Slo gene in corporal tissue. Eur Urol 2007;52:1229-37
   PubMedGoogle Scholar
• Christ GJ, Day N, Santizo C, et al. Intracorporal injection of hSlo cDNA restores erectile capacity in STZ-diabetic F-344 rats in vivo. Am J Physiol Heart Circ Physiol 2004;287:H1544-53
   PubMed Web of Science ®Google Scholar
• Abdelbaky TM, Brock GB, Huynh H. Improvement of erectile function in diabetic rats by insulin: possible role of the insulin-like growth factor system. Endocrinology 1998;139:3143-7
   PubMedGoogle Scholar
• Usta MF, Bivalacqua TJ, Koksal IT, et al. The protective effect of aminoguanidine on erectile function in diabetic rats is not related to the timing of treatment. BJU Int 2004;94:429-32
   PubMed Web of Science ®Google Scholar
• Shirai M, Yamanaka M, Shiina H, et al. Androgen, estrogen, and progesterone receptor gene regulation during diabetic erectile dysfunction and insulin treatment. Urology 2004;64:1244-9
   PubMedGoogle Scholar
• Montorsi F, McDermott TE, Morgan R, et al. Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology 2000;53:1011-8
   Google Scholar
• Salerian AJ, Deibler WE, Vittone BJ, et al. Sildenafil for psychotropic-induced sexual dysfunction in 31 women and 61 men. J Sex Marital Ther 2000;26:133-40
   PubMed Web of Science ®Google Scholar
• Eardley I, Gentile V, Austoni E, et al. Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction. BJU Int 2004;94:871-7
   PubMed Web of Science ®Google Scholar
• Price DE, Gingell JC, Gepi-Attee S, et al. Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men. Diabet Med 1998;15:821-5
   PubMedGoogle Scholar
• Israilov S, Shmuely J, Niv E, et al. Evaluation of a progressive treatment program for erectile dysfunction in patients with diabetes mellitus. Int J Impot Res 2005;17:431-6
   PubMedGoogle Scholar
• Behrend L, Vibe-Petersen J, Perrild H. Sildenafil in the treatment of erectile dysfunction in men with diabetes: demand, efficacy and patient satisfaction. Int J Impot Res 2005;17:264-9
   PubMedGoogle Scholar
• Safarinejad MR. Oral sildenafil in the treatment of erectile dysfunction in diabetic men: a randomized double-blind and placebo-controlled study. J Diabetes Complications 2004;18:205-10
   PubMed Web of Science ®Google Scholar
• Rendell MS, Rajfer J, Wicker PA, et al. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999;281:421-6
   PubMed Web of Science ®Google Scholar
• Blonde L. Sildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebo-controlled trials. Curr Med Res Opin 2006;22:2111-20
   PubMed Web of Science ®Google Scholar
• Boulton AJ, Selam JL, Sweeney M, et al. Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus. Diabetologia 2001;44:1296-301
   PubMed Web of Science ®Google Scholar
• Stuckey BG, Jadzinsky MN, Murphy LJ, et al. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care 2003;26:279-84
   PubMed Web of Science ®Google Scholar
• Dietz U, Tries HP, Merkle W, et al. Sildenafil does not change coronary flow reserve in diabetics with erectile dysfunction. Dtsch Med Wochenschr 2003;128:190-5
   PubMedGoogle Scholar
• Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003;26:777-83
   PubMed Web of Science ®Google Scholar
• Ishii N, Nagao K, Fujikawa K, et al. Vardenafil 20-mg demonstrated superior efficacy to 10-mg in Japanese men with diabetes mellitus suffering from erectile dysfunction. Int J Urol 2006;13:1066-72
   PubMed Web of Science ®Google Scholar
• Ziegler D, Merfort F, Van Ahlen H, et al. Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. J Sex Med 2006;3:883-91
   PubMed Web of Science ®Google Scholar
• Fonseca V, Seftel A, Denne J, et al. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. Diabetologia 2004;47:1914-23
   PubMed Web of Science ®Google Scholar
• Buvat J, Van Ahlen H, Schmitt H, et al. Efficacy and safety of two dosing regimens of tadalafil and patterns of sexual activity in men with diabetes mellitus and erectile dysfunction: scheduled use vs. on-demand regimen evaluation (SURE) study in 14 European countries. J Sex Med 2006;3:512-20
   PubMed Web of Science ®Google Scholar
• Kang KK, Choi SM, Ahn GJ, et al. The effect of DA-8159 on corpus cavernosal smooth muscle relaxation and penile erection in diabetic rabbits. Urol Res 2004;32:107-11
   PubMedGoogle Scholar
• Ahn GJ, Sohn YS, Kang KK, et al. The effect of PDE5 inhibition on the erectile function in streptozotocin-induced diabetic rats. Int J Impot Res 2005;17:134-41
   PubMedGoogle Scholar
• Yu JY, Kang KK, Yoo M, et al. Penile erectile responses to electric stimulation are enhanced by a new phosphodiesterase type-5 inhibitor. Int J Urol 2005;12:299-304
   PubMedGoogle Scholar
• Ahn GJ, Yu JY, Choi SM, et al. Chronic administration of phosphodiesterase 5 inhibitor improves erectile and endothelial function in a rat model of diabetes. Int J Androl 2005;28:260-6
   PubMed Web of Science ®Google Scholar
• Seftel AD. Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. Clin Cardiol 2004;27:I14-19
   PubMed Web of Science ®Google Scholar
• Behr-Roussel D, Gorny D, Mevel K, et al. Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis. Eur Urol 2005;47:87-91
   PubMed Web of Science ®Google Scholar
• Rosano GM, Aversa A, Vitale C, et al. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005;47:214-20; discussion 220-2
   PubMed Web of Science ®Google Scholar
• Aversa A, Greco E, Bruzziches R, et al. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res 2007;19:200-7
   PubMed Web of Science ®Google Scholar
• Schafer A, Fraccarollo D, Pfortscj S, et al. Improvement of vascular function by acute and chronic treatment with the PDE-5 inhibitor sildenafil in experimental diabetes mellitus. Br J Pharmacol 2007
   PubMedGoogle Scholar
• Aversa A, Bruzziches R, Vitale C, et al. Chronic sildenafil in men with diabetes and erectile dysfunction. Expert Opin Drug Metab Toxicol 2007;3:451-64
   PubMed Web of Science ®Google Scholar
• Kalinchenko SY, Kozlov GI, Gontcharov NP, et al. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 2003;6:94-9
   PubMedGoogle Scholar
• Zhang XH, Filippi S, Morelli A, et al. Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes. J Sex Med 2006;3:253-64; discussion 264-5, author reply 265-6
   PubMed Web of Science ®Google Scholar
• Montague DK, Jarow JP, Broderick GA, et al. Chapter 1: The management of erectile dysfunction: an AUA update. J Urol 2005;174:230-9
   PubMed Web of Science ®Google Scholar
• Gontero P, D'Antonio R, Pretti G, et al. Clinical efficacy of Apomorphine SL in erectile dysfunction of diabetic men. Int J Impot Res 2005;17:80-5
   PubMed Web of Science ®Google Scholar
• De Young L, Yu D, Freeman D, et al. Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model. Int J Impot Res 2003;15:347-54
   PubMedGoogle Scholar
• Gentile V, Vicini P, Prigiotti G, et al. Preliminary observations on the use of propionyl-L-carnitine in combination with sildenafil in patients with erectile dysfunction and diabetes. Curr Med Res Opin 2004;20:1377-84
   PubMed Web of Science ®Google Scholar
• Morano S, Mandosi E, Fallarino M, et al. Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study. Eur Urol 52(6):1768-76
   PubMedGoogle Scholar
• Vrijhof HJ, Delaere KP. Vacuum constriction devices in erectile dysfunction: acceptance and effectiveness in patients with impotence of organic or mixed aetiology. Br J Urol 1994;74:102-5
   PubMedGoogle Scholar
• Price DE, Cooksey G, Jehu D, et al. The management of impotence in diabetic men by vacuum tumescence therapy. Diabet Med 1991;8:964-7
   PubMedGoogle Scholar
• Virag R. Intracavernous injection of papaverine for erectile failure. Lancet 1982;2:938
   PubMed Web of Science ®Google Scholar
• Broderick GA, Lue TF. Evaluation and nonsurgical management of erectile dysfunction and priapism. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, editors. Campbell's Urology, 8th ed. Philadelphia: Saunders Publishers; 2002. p. 1619-71
   Google Scholar
• Bell DS, Cutter GR, Hayne VB, et al. Factors predicting efficacy of phentolamine-papaverine intracorporeal injection for treatment of erectile dysfunction in diabetic male. Urology 1992;40:36-40
   PubMedGoogle Scholar
• Lane BR, Ausmundson SJ, Butler RS, et al. Use of a visual analog scale to assess pain of injection with intracavernous injection therapy. J Sex Med 2005;2:428-31
   PubMedGoogle Scholar
• Perimenis P, Gyftopoulos K, Athanasopoulos A, et al. Diabetic impotence treated by intracavernosal injections: high treatment compliance and increasing dosage of vaso-active drugs. Eur Urol 2001;40:398-402; discussion 403
   PubMedGoogle Scholar
• Lepore G, Nosari I. Efficacy of oral sildenafil in the treatment of erectile dysfunction in diabetic men with positive response to intracavernosal injection of alprostadil. Diabetes Care 2001;24:409-11
   PubMed Web of Science ®Google Scholar
• Perimenis P, Markou S, Gyftopoulos K, et al. Switching from long-term treatment with self-injections to oral sildenafil in diabetic patients with severe erectile dysfunction. Eur Urol 2002;41:387-91
   PubMed Web of Science ®Google Scholar
• Fedele D, Coscelli C, Cucinotta D, et al. Management of erectile dysfunction in diabetic subjects: results from a survey of 400 diabetes centres in Italy. Diabetes Nutr Metab 2001;14:277-82
   PubMedGoogle Scholar
• Heaton JP, Lording D, Liu SN, et al. Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men. Int J Impot Res 2001;13:317-21
   PubMed Web of Science ®Google Scholar
• Perimenis P, Konstantinopoulos A, Perimeni PP, et al. Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction. Asian J Androl 2006;8:219-24
   PubMed Web of Science ®Google Scholar
• Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med 1997;336:1-7
   PubMed Web of Science ®Google Scholar
• Li MK, Lim PH, Wong MY, et al. Transurethral alprostadil for the treatment of erectile dysfunction: results of a multicentre trial. Ann Acad Med Singapore 2000;29:727-31
   PubMedGoogle Scholar
• Carrion H, Bakshandeh K, Rodriguez A, et al. Small-Carrion penile prosthesis for the management of diabetic impotence. South Med J 1980;73:310-1
   PubMedGoogle Scholar
• Jaworski TM, Richards JS, Lloyd LK. Retrospective review of sexual and marital satisfaction of spinal cord injury and diabetic males post penile injection or implant. Urology 1992;40:127-31
   PubMedGoogle Scholar
• Peterson HR, Best JD, Berger R, et al. Attitudes of diabetic men after implantation of a semi-rigid penile prosthesis. Diabetes Care 1985;8:156-60
   PubMed Web of Science ®Google Scholar
• Abouassaly R, Angermeier KW, Montague DK. Risk of infection with an antibiotic coated penile prosthesis at device replacement for mechanical failure. J Urol 2006;176:2471-3
   PubMedGoogle Scholar
• Bishop JR, Moul JW, Sihelnik SA, et al. Use of glycosylated hemoglobin to identify diabetics at high risk for penile periprosthetic infections. J Urol 1992;147:386-8
   PubMed Web of Science ®Google Scholar
• Wilson SK, Carson CC, Cleves MA, et al. Quantifying risk of penile prosthesis infection with elevated glycosylated hemoglobin. J Urol 1998;159:1537-9; discussion 1539-40
   PubMed Web of Science ®Google Scholar
• Dai YT, Chen Y, Yao LS, et al. Expression of nerve growth factor in cavernous tissue and its effects on the treatment of rats with diabetic erectile dysfunction. Zhonghua Nan Ke Xue 2005;11:748-51, 54
   PubMedGoogle Scholar
• Shen ZJ, Wang H, Lu YL, et al. Gene transfer of vasoactive intestinal polypeptide into the penis improves erectile response in the diabetic rat. BJU Int 2005;95:890-4
   PubMedGoogle Scholar
• Jesmin S, Zaedi S, Yamaguchi N, et al. Effects of dual endothelin receptor antagonist on antiapoptotic marker Bcl-2 expression in streptozotocin-induced diabetic rats. Exp Biol Med (Maywood) 2006;231:1034-9
   PubMedGoogle Scholar
• Anaka M, Shirai M, Shiina H, et al. Vascular endothelial growth factor restores erectile function through inhibition of apoptosis in diabetic rat penile crura. J Urol 2005;173:318-23
   PubMedGoogle Scholar
• Tong YC, Hung YC, Lin SN, et al. Treatment effect of “ryu-wei-ti-huang-wan” (a Chinese herbal prescription) on the sexual performance of male rats with streptozotocin-induced diabetes. Urol Int 1996;57:230-4
   PubMedGoogle Scholar
• Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-30
   Google Scholar